Abstract
Differences in baseline features and follow-up among patients with chronic myeloid leukemia (CML) according to age at diagnosis have been recently reported in cohorts from clinical controlled trials (Castagnetti F et al, 2015). To evaluate this issue in a real-life setting, we revised 207 consecutive CML patients treated at our Institution with imatinib frontline from 6/2002 to 6/2013, dividing them in young adults (>20 <45 years) (YA), middle-aged adults (≥45 <65 years) (MA) and elderly (≥65 years) (EL). The main features at baseline of the whole cohort and of the 3 age groups are reported in the Table.
. | ALL . | YA . | MA . | EL . | p . |
---|---|---|---|---|---|
N° of patients | 207 | 61 | 72 | 74 | |
M/F | 108/89 | 30/31 | 40/32 | 38/36 | 0.752 |
Median WBC (x 109/l) IQR | 66.1 (32.7 - 119.0) | 109.8 (65.9 - 148.0) | 59.5 (31.3 - 126.6) | 40.1 (26.5 - 81.4) | <0.001 |
Median Hb (g/dl) (IQR) | 12.5 (11.0 - 13.5) | 11.7 (9.8 - 12.7) | 12.7 (11.0 - 14.2) | 12.8 (11.3 - 13.7) | 0.002 |
Median PLT (x 109/l) IQR | 414 (275 - 616) | 445 (291 - 597) | 378 (262 - 546) | 457 (271 - 732) | 0.287 |
Spleen enlargement (>5cm) N° (%) | 17 (8.3) | 11 (18.3) | 4 (5.6) | 2 (2.7) | 0.003 |
Sokal score (N°) Low/Int/High | 89/93/20 | 47/9/3 | 38/27/5 | 4/57/12 | <0.001 |
Comorbidities ≥ 2, N° (%) | 77 (37.2) | 5 (8.1) | 26 (36.1) | 46 (62.1) | <0.001 |
. | ALL . | YA . | MA . | EL . | p . |
---|---|---|---|---|---|
N° of patients | 207 | 61 | 72 | 74 | |
M/F | 108/89 | 30/31 | 40/32 | 38/36 | 0.752 |
Median WBC (x 109/l) IQR | 66.1 (32.7 - 119.0) | 109.8 (65.9 - 148.0) | 59.5 (31.3 - 126.6) | 40.1 (26.5 - 81.4) | <0.001 |
Median Hb (g/dl) (IQR) | 12.5 (11.0 - 13.5) | 11.7 (9.8 - 12.7) | 12.7 (11.0 - 14.2) | 12.8 (11.3 - 13.7) | 0.002 |
Median PLT (x 109/l) IQR | 414 (275 - 616) | 445 (291 - 597) | 378 (262 - 546) | 457 (271 - 732) | 0.287 |
Spleen enlargement (>5cm) N° (%) | 17 (8.3) | 11 (18.3) | 4 (5.6) | 2 (2.7) | 0.003 |
Sokal score (N°) Low/Int/High | 89/93/20 | 47/9/3 | 38/27/5 | 4/57/12 | <0.001 |
Comorbidities ≥ 2, N° (%) | 77 (37.2) | 5 (8.1) | 26 (36.1) | 46 (62.1) | <0.001 |
The rates of complete cytogenetic response (CCyR) were similar (86.4% in YA, 95.5% in MA and 91.0% in EL, p=0.227) while the rate of major molecular response was higher in the MA group (89.7% vs 63.8% in YA and 75.8% in EL, p=0.001). The number of events (permanent discontinuation due to toxicity, primary or secondary resistance, any death for CML related or unrelated causes) was lower in the MA group [8 (11.1%) vs 21 (34.4%) in YA and 28 (37.8%) in EL, p=0.001]: no difference was observed in the rate of evolution to blastic phase [3 (4.9%) in YA, 1 (1.4%) in MA and 2 (2.7%) in EL, p=0.478]. The number of deaths was higher in the EL group [12 (16.2%) vs 2 (3.2%) in YA and 0 in MA, p<0.001]: it is worth of note, however, that 11/12 deaths in the EL group were not related to CML progression. The 4-year event-free survival (EFS) for the whole cohort was 73.5% (95%CI 67.0 - 80.0): the 4-year EFS in the MA group [92.0% (95%CI 85.1 - 98.9)] was significantly higher than in YA group [67.3% (95%CI 55.1 - 79.5)] and in EL group [61.1% (95%CI 49.5 - 73.7)] (p=0.001). The 4-year overall survival (OS) for the whole cohort was 94.4% (95%CI 90.9 - 97.9): the 4-year OS in the EL group [72.4.% (95%CI 56.9 - 87.9)] was significantly lower than in YA group [96.3% (95%CI 91.2 - 100)] and in MA group (100%) (p<0.001). In conclusion, age at diagnosis influences significantly the course of CML patients treated with imatinib: the MA group has the best follow-up with an excellent OS and EFS, while the relatively lower OS and EFS in the EL group are clearly related to the incidence of unrelated deaths like in the general aged population. A possible explanation of the counterintuitive worse course of YA group is the delayed diagnosis in these patients (higher WBC counts, lower Hb levels, higher rate of spleen enlargement > 5 cm) compared to aged patients, who have often concomitant diseases and make routinely blood analyses: however, a more aggressive biology of CML in YA could not be excluded and warrants further investigations.
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.
![](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/126/23/10.1182_blood.v126.23.4038.4038/3/m_inf01.jpeg?Expires=1726940087&Signature=0D5TripPVGkPlZ11iP3YE0-ZJPicGcvnt3oBBF9Z0Ymb8aP9GnZ1GzzbUinuF6bxHf6p1QuGMCrC-W~Zh8JsbIeP4QHP9-2AuP-uVvxxDFSoQhGwGMzwHCKQN~vZc5o7n387HqQYgt2jkyETRkKTpdeCj0bQWjiOZTOWl1spbzb1KJ4grSnlPoqLY9Sjn2Nhs3vioP1xY4YTCHAhaOz53cSMCg~PXRkqpOJfjOT0xiiKFskJ8dsSxFDU6D6XoMAMn3fxmAHx~oHnp~-BvdTlut2PsZWW0s8TMH4jPDkKX0W1xS4MY9sCY~vv2OoYS9bujVCv5R0B5aHBoam9PhmulQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
This icon denotes a clinically relevant abstract
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal